Long COVID and ME/CFS: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-6 1
• ACE2 0
• mTOR 0
• NLRP3 0
• PI3K 0
• TNF 0
• AMPK 0
• CD38 1
• GLP-1 0
• IL-15 1
• JAK 0
• MMP-9 0
• AKT 0
• APOE 0
• AQP4 0
• BDNF 0
• CD19 1
• CD40 0
• HIF-1 0
• HSP90 0
• IL-1 0
• IL-17 0
• NMDA 0
• PD-1 1
• SGLT2 0
• TFEB 0
• TP53 0
• VEGF 0

24 of 936 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Navigating Work-Nonwork Boundaries in Hybrid Work: Exploring Career Trajectories and Intersectional Challenges for Professional Women (HYBWORKEXP)

  Ism Vadybos Ir Ekonomikos Universitetas Uab· Vilnius, Lithuania· EU contribution €196,976· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Nutrition AI for Well-Being and Social Inclusion (NutriWell)

  Innova Living· Sofia, Bulgaria· EU contribution €499,629· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €7,588,595· until Jun 2030· 12 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Kefiran: Harnessing Exopolysaccharide bioActivities beneficiaL To Health (KHEALTH)

  Teagasc - Agriculture and Food Development Authority· Carlow, Ireland· EU contribution €252,729· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Housing, Inequality, and Price-Setting: Theory, Evidence, and Ramifications for the Macroeconomy (HIPSTERMacro)

  Stockholms Universitet· Stockholm, Sweden· EU contribution €1,504,353· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

5 of 17 running projects, newest first. Listed amounts together: €68.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

  NCT05876377· Pfizer· Updated 15 Sept 2026

  “Study discontinued due to questions of data validity and bias in data which would limit causal inference and estimation of vaccine effectiveness.”Registry text, quoted unchanged. Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Vanderbilt University Medical Center· Updated 9 Sept 2026

  “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”Registry text, quoted unchanged. Source

• Terminated

  CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19

  NCT05530317· University of California, San Francisco· Updated 13 Aug 2026

  “PI changed institutions, exploring restarting at new institution”Registry text, quoted unchanged. Source

• Withdrawn

  Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID

  NCT07714889· Toivoa Inc· Updated 29 Jul 2026

  “This study does not meet the clinical trial definition under FDAAA 801 / NIH policy - participants aren't prospectively assigned to an intervention, and no biomedical or behavioral outcome is evaluated.”Registry text, quoted unchanged. Source

• Withdrawn

  Education of Medical Staff to Post Acute Covid susTained sYmptoms

  NCT06082258· Assistance Publique - Hôpitaux de Paris· Updated 1 Jul 2026

  “The research was not feasible due to administrative and organizational constraints.”Registry text, quoted unchanged. Source

• Terminated

  Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation

  NCT05967052· National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland· Updated 17 Jun 2026

  “occurrence of scientific risk”Registry text, quoted unchanged. Source

• Suspended

  Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

  NCT03807973· University of Alabama at Birmingham· Updated 2 Jun 2026

  “Lost funding.”Registry text, quoted unchanged. Source

• Terminated

  Functional and Affective Effects of a Brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome

  NCT07573709· Hospital Donostia· Updated 7 May 2026

  “Not stopped. It is completed.”Registry text, quoted unchanged. Source

• Terminated

  Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

  NCT05986422· Charite University, Berlin, Germany· Updated 5 May 2026

  “Following a recommendation from the Data Safety Monitoring Board (DSMB).”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

  NCT07388550· National Institute of Neurological Disorders and Stroke (NINDS)· Source

• Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study

  NCT07874217· Oxford Brookes University· Source

• LIFT: Life Improvement Trial

  NCT06366724· Brigham and Women's Hospital· Source

• The Precision Mito- Mito Map COMPASS Study

  NCT07856121· AI Agent Vault, Inc. d/b/a Precision Mito· Source

• Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

  NCT05615415· NYU Langone Health· Source

• Heat thErapy And mobiLity in COVID-19 Survivors

  NCT06928116· University of Nebraska· Source

• Etiology Analysis of Chronic Cough After COVID-19 Infection and Research on the Efficacy of ICS or ICS/LABA

  NCT06503939· Xiangya Hospital of Central South University· Source

• RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue

  NCT06739720· The University of Hong Kong· Source

• Autoimmune Intervention Mastery Course Study

  NCT05057676· Terry L. Wahls· Source

• Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

  NCT06821087· University of Texas at Austin· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 1
• Mendelian Randomization Analysis 4
• Gene Expression Profiling 20
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Proteomics 40
• Metabolomics 20
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 49
• Machine Learning 32
• Deep Learning 5
• Cohort Studies 92
• Genome-Wide Association Study 11

• The post-acute effects of COVID-19 are not associated with robust long-term regional or global brain volumetric changes: A Bayesian meta-analytic evidence.

  Neurosci Biobehav Rev, Sept 2026

• FreeSurfer-based amygdala subfield volumetry in long COVID and ME/CFS: clinical and immunological correlations.

  Front Neurol, Sept 2026

• Five-year Quantitative Chest CT and Hyperpolarized Xenon 129 Ventilation MRI Findings in Survivors of COVID-19 Pneumonia.

  Radiology, Sept 2026

  Chuansheng Zheng

• Central origin of fatigability in Myalgic encephalomyelitis/chronic fatigue syndrome revealed by multimodal neuroimaging.

  Neuroimage Clin, Jul 2026

• Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial.

  Nat Med, Jul 2026

• Cerebral gray matter volumes in long-term post-COVID patients are associated with peripheral kynurenine pathway metabolites and the severity of depressive symptoms.

  Brain Behav Immun, Jul 2026

• Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol.

  BMJ Open, Jul 2026

• Cardiac Magnetic Resonance Imaging Study on Cardiovascular Involvement >60 Days Post COVID-19 Recovery.

  J Assoc Physicians India, Jul 2026

• Genetic evidence that advanced COVID-19 accelerates longitudinal brain atrophy: A Mendelian randomization study.

  Medicine (Baltimore), Jun 2026

• Pulmonary and cerebral damage in COVID-19 survivors: is there any association?

  Ann Med, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.